Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery

We aimed to investigate short-term outcomes of the XINSOEB bioresorbable sirolimus-eluting scaffold in human coronary artery.

2016

08-12

科学家称五年内将3D打印人类心脏

美国科学家表示，未来几年之内将3D打印组装完整的心脏组织，并能与患者身体完美地结合在一起。

2016

06-24

阿迈特专家委员会成立

五月的北京，惠风和畅，春意盎然，鲜花怒放。在这美好的季节里，美国工程院院士、美国科学医学院院士和美国发明家学院院士、美国Rice大学的Antonios G. Mikos教授专程从美国休斯敦飞到北京，与其他几位专家一起从北京阿迈特医疗器械有限公司董事长刘青博士手中接过专家聘书，至此，一支由国内外顶尖专家组成的阿迈特医疗器械有限公司专家委员会正式宣告成立。在随后召开的第一届阿迈特专家委员会上， Mikos教授对公司研发的3D血管支架精密制造专利技术给予了高度评价。

2016

06-01

中国心脏支架产业发展报告

增速之所以放缓主要归于三个缘由：一是高值耗材招标带来了降价风潮;二是由于患者多涌向三级医院，因此三级医院手术量基本饱和，目前基本处于平衡小幅增长的阶段;三则是广大县级地区受限于当地的医疗资源限制和新农合报销比例，增长缓慢。

2015

08-27

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

2015

08-04

Outcomes with bioabsorbable vascular scaffolds versus everolimus-eluting stents Insights from randomized trials

Bioresorbable vascular scaffolds (BVS) have been shown to be non-inferior to second generation drug eluting stents in recent clinical trials. However, the trials were not powered for individual endpoints and there is concern for increased device thrombosis with BVS.

2015

08-04

Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled

Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease treated with percutaneous revascularisation.

2015

08-04

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimuseluting metallic stents in patients with coronary artery disease: ABSORB Japan

superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown.

2015

08-03

首届中国创新成果交流会在广州举办

第一届中国创新科技成果交流会5月22-23日在广州白云国际会议中心举行。我公司由北京生物医学工程学会推荐参加了此次创新成果交易会，本届科交会共收集到1300多项科研成果进行集中展示推介，经过前期对接，目前已有20项科研成果达成初步落地意向，有望在广州得到转化，涉及投资金额约20亿元。

2015

05-26

3D打印：还会给你更多惊喜

近日，公司董事长刘青博士接受《人民日报》采访，对阿迈特研发的3D支架产品进行了介绍，并对3D打印技术的现状及未来发展前景发表了自己的见解，原文如下：

2014

09-02

< 1...11121314 > 前往 页

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

 

联系我们

地址：北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话：010-6297-7955             邮箱：amt@ametcorp.com

图片名称

微信联系

@Copyright 2022 北京阿迈特医疗器械有限公司 All rights reserved   版权所有

京ICP备11028039号    网站建设：中企动力  南京